Low-dose clofarabine in combination with a standard remission induction in patients aged 18–60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial

Selleslag, Dominik; Suciu, Stefan; Meloni, Giovanna; Muus, Petra; Halkes, Constantijn J.M.; Venditti, Adriano; Ramadan, Safaa; Pruijt, Hans; Meert, Liv; Vignetti, Marco; Marie, Jean Pierre; Wittnebel, Sébastian; Witte, Théo de; Amadori, Sergio; Willemze, R.; Baron, Frédéric

doi:10.3324/haematol.2016.153130

Cited by 5 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secondary acute myeloid leukaemia (AML) has been classified as AML occurring after prior myeloid disease including myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN) while therapy-related AML (tAML) has been defined as AML occurring after exposure to radiation or chemotherapy [1,2]. Many prior studies have grouped these two categories as 'secondary AML (sAML)' [3][4][5][6]. In most reports, sAML represents approximately 25% of all AML patients [7,8].…”

Section: Introductionmentioning

confidence: 99%

Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission

et al. 2019

View full text Add to dashboard Cite

Israel). Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission. J Intern Med 2019; 285: 446-454.Background. We conducted a retrospective survey within the European Society for Blood and Marrow Transplantation (EBMT) registry to assess the outcomes of cord blood transplantation (CBT) in secondary acute myeloid leukaemia (sAML).Methods. Inclusion criteria consisted of ≥18 years of age, sAML, first CBT between 2002 and 2016, and either first complete remission (CR) or active disease at CBT.Results. One hundred forty-six patients met the study inclusion criteria. Status at transplantation was first CR (n = 97), primary refractory sAML (n = 30) or relapsed (n = 19) sAML. Neutrophil engraftment was achieved in 118 patients while the remaining 25 patients (17%) failed to engraft. This includes 13% of patients transplanted in first CR versus 30% of those transplanted with active disease (P = 0.008). Two-year incidences of relapse were 25% in first CR patients versus 36% in those with advanced disease (P = 0.06) while 2-year incidences of nonrelapse mortality were 35% and 49% (P = 0.03), respectively. At 2-year overall survival, leukaemia-free survival and graft-versus-host disease (GVHD)-free relapse-free survival were 42% vs. 19% (P < 0.001), 40% vs. 16% (P < 0.001), and 26% vs. 12% (P = 0.002) in first CR patients versus those with advanced disease, respectively. Conclusions.We report here the first study of CBT in a large cohort of sAML patients. Main observation was that CBT rescued approximately 40% of patients with sAML in first CR.

show abstract

Section: Introductionmentioning

confidence: 99%

Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Although the overall survival (OS) in younger acute myeloid leukemia (AML) patients has improved in the recent decades, disease relapse remains the first cause of death in younger patients with AML [1][2][3][4][5][6]. Approximately 60% of younger patients diagnosed with AML have chromosomal aberrations in their leukemic cells [1].…”

Section: Introductionmentioning

confidence: 99%

Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15–60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Nevertheless, high-dose conditioning regimen administered before myeloablative allo-HCT as well as intensive chemotherapy regimens used to treat AML still results in prolonged bone marrow aplasia and particularly prolonged neutropenia that often leads to bacterial and/or fungal infections [3][4][5][6]. This is particularly the case when umbilical cord blood (UCB) is chosen as stem cell source for allo-HCT [4], or when the intensity of the chemotherapy is increased in the induction or consolidation chemotherapy course of AML [7].…”

Section: Introductionmentioning

confidence: 99%

Novel strategies for improving hematopoietic reconstruction after allogeneic hematopoietic stem cell transplantation or intensive chemotherapy

Baron

Nagler

2016

Expert Opinion on Biological Therapy

Self Cite

View full text Add to dashboard Cite

Introduction: High-dose conditioning regimens for allogeneic hematopoietic cell transplantation (allo-HCT) as well as intensive poly-chemotherapy for acute myeloid leukemia (AML) induce prolonged periods of neutropenia. The duration of the neutropenia is particularly long following umbilical cord blood transplantation (UCBT). Areas covered: After briefly reviewing the impact of hematopoietic growth factors administration to hasten hematologic reconstitution after allo-HCT or intensive AML chemotherapy, this article summarizes recent approaches that have been investigated to prompt hematologic reconstruction after UCBT or intensive AML chemotherapy. Expert opinion: In the allo-HCT setting, administration of G-CSF or GM-CSF shortened the duration of the neutropenia but failed to decrease infection-related mortality or to improve survival. Novel approaches to hasten hematological reconstruction after UCBT such as double UCBT with expansion of one of the 2 UCB units with Notch ligand, mesenchymal stromal cells, nicotinamide, or StemRegenin 1, co-transplanting a single UCB unit with HLA-haploidentical CD34+ cells, or increasing UCB HSC homing to marrow niches via direct intra bone UCB administration, pulse treatment with dmPGE2 or enforced fucosylation are promising and deserve further investigations in prospective phase III studies. In the AML setting, G-CSF or GM-CSF administration after intensive chemotherapy decreased the duration of the neutropenia without improving survival. ARTICLE HISTORY

show abstract

Low-dose clofarabine in combination with a standard remission induction in patients aged 18–60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial

Cited by 5 publications

References 12 publications

Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission

Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission

Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15–60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials

Novel strategies for improving hematopoietic reconstruction after allogeneic hematopoietic stem cell transplantation or intensive chemotherapy

Contact Info

Product

Resources

About